#13

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 294-120 PCT/US	SERIAL NO. 10/049,473
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT de Groot, et al.	CONFIRMATION NO. 4102
(Use several sheets if necessary)	FILING DATE July 30, 2002	GROUP 1645

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES	TRANSLATION NO
		WO 00/06737	2/20/00	~~PCT~~ WO				
		WO 98/18930	5/7/98	~~PCT~~ WO				
		WO 97/37026	10/9/97	~~PCT~~ WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		1.	Jansen, W.T.M., et al., "Use of Highly Encapsulated *Streptococcus pneumoniae* Strains in a Flow-Cytometric Assay for Assessment of the Phagocytic Capacity of Serotype-Specific Antibodies", *Clinical and Diagnostic Laboratory Immunology* Sept. 1998, 5(5):703-710.
		2.	McDaniel, Larry S., et al., "Comparison of the PspA Sequence from *Streptococcus pneumoniae* EF5668 to the Previously Identified PspA Sequence from Strain Rx1 and Ability of PspA from EF5668 to Elicit Protection against Pneumococci of Different Capsular Types", *Infection and Immunity* Oct. 1998, 66(10):4748-4754.
		3.	Overweg, K., et al., "The Putative Proteinase Maturation Protein A of *Streptococcus pneumoniae* is a Conserved Surface Protein with Potential to Elicit Protective Immune Responses", *Infection and Immunity* 2000, 68(7):4180-4188.

175044_1

EXAMINER _____ DATE CONSIDERED 10/27/

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.